Press release
Relapsed/Refractory Acute Myeloid Leukemia (AML) Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Antengene, Servier, Novartis, ImmunoGen, Ascentage, Kronos Bio, Maxinovel, Karyopharm
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 50+ key pharma and biotech companies are working on 50+ pipeline drugs in the Relapsed/Refractory Acute Myeloid Leukemia therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years."Relapsed/Refractory Acute Myeloid Leukemia (AML) Pipeline Insight" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Relapsed/Refractory Acute Myeloid Leukemia Therapeutics Market.
The report provides a detailed description of the Relapsed/Refractory Acute Myeloid Leukemia drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Relapsed/Refractory Acute Myeloid Leukemia Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Relapsed/Refractory Acute Myeloid Leukemia (AML) Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Relapsed/Refractory Acute Myeloid Leukemia therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Relapsed/Refractory Acute Myeloid Leukemia treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Relapsed/Refractory Acute Myeloid Leukemia drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Relapsed/Refractory Acute Myeloid Leukemia treatment market.
Learn More about the Clinical and Commercial Development Activities in the Relapsed/Refractory Acute Myeloid Leukemia Therapeutics Domain @
https://www.delveinsight.com/report-store/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Relapsed/Refractory Acute Myeloid Leukemia (AML) Therapeutics Analysis
There are approx. 50+ key companies developing therapies for Relapsed/Refractory acute myeloid leukemia (AML). Currently, Ascentage Pharma is leading the therapeutics market with its Relapsed/refractory acute myeloid leukemia (AML) drug candidates in the most advanced stage of clinical development.
Relapsed/Refractory Acute Myeloid Leukemia (AML) Companies in the Therapeutics Market Include:
• Ascentage Pharma
• Cullinan Oncology
• Kronos Bio
• Maxinovel Pharmaceuticals
• AB Science
• Ciclo Med
• Karyopharm Therapeutics
• Antengene Corporation
• Glyco Mimetics
• Servier
• Novartis
• ImmunoGen
And Many Others
Emerging and Marketed Relapsed/Refractory Acute Myeloid Leukemia (AML) Therapies Covered in the Report Include:
• APG-2575: Ascentage Pharma
• CLN 049: Cullinan Oncology
• Lanraplenib: Kronos Bio
• CYAD-02: Celyad Oncology
• FHD-286: Foghorn Therapeutics
• ONC201: Oncoceutics
• AB8939: AB Science
• Uproleselan: GlycoMimetics
• Crenolanib: AROG Pharmaceuticals
• Keytruda: Merck & Co
And Many Others
Get an in-depth Assessment of the Emerging Therapies and Relapsed/Refractory Acute Myeloid Leukemia Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Relapsed/Refractory Acute Myeloid Leukemia Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates
Mechanism of Action of the Emerging Therapies
• Fms-like tyrosine kinase 3 inhibitors
• E-selectin inhibitor
• SMARCA4 protein inhibitor
• Endopeptidase Clp stimulants
• T lymphocyte replacement
• Programmed cell death-1 receptor antagonists
• Natural killer cell stimulant
• Tubulin polymerisation inhibitor
Route of Administration
Relapsed/Refractory acute myeloid leukemia (AML) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Molecule Type
Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule
Request for Sample PDF to Understand More About the Relapsed/Refractory Acute Myeloid Leukemia Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Relapsed/Refractory Acute Myeloid Leukemia Current Treatment Patterns
4. Relapsed/Refractory Acute Myeloid Leukemia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Relapsed/Refractory Acute Myeloid Leukemia Late-Stage Products (Phase-III)
7. Relapsed/Refractory Acute Myeloid Leukemia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Relapsed/Refractory Acute Myeloid Leukemia Discontinued Products
13. Relapsed/Refractory Acute Myeloid Leukemia Product Profiles
14. Relapsed/Refractory Acute Myeloid Leukemia Companies
15. Relapsed/Refractory Acute Myeloid Leukemia Drugs
16. Dormant and Discontinued Products
17. Relapsed/Refractory Acute Myeloid Leukemia Unmet Needs
18. Relapsed/Refractory Acute Myeloid Leukemia Future Perspectives
19. Relapsed/Refractory Acute Myeloid Leukemia Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Relapsed/Refractory Acute Myeloid Leukemia (AML) Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Antengene, Servier, Novartis, ImmunoGen, Ascentage, Kronos Bio, Maxinovel, Karyopharm here
News-ID: 3343774 • Views: …
More Releases from DelveInsight Business Research LLP

Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical S …
DelveInsight's "Myelofibrosis Pipeline Insight" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis…

Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Cu …
DelveInsight's "Hemophilia Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia…

DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinica …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive…

Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action …
DelveInsight's "Hearing Loss Pipeline Insight" report provides comprehensive insights about 32+ companies and 35+ pipeline drugs in Hthe earing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hearing Loss therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights!…
More Releases for Relapsed/Refractory
Relapsed/Refractory Acute Myeloid Pipeline Therapeutics Assessment Report 2024 ( …
DelveInsight's, "Relapsed/refractory acute myeloid leukemia (AML) Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the Relapsed/Refractory Acute Myeloid Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
…
Relapsed/Refractory Acute Myeloid Leukemia Clinical Trials, Treatment Drugs, Pip …
DelveInsight's, "Relapsed/refractory acute myeloid leukemia (AML) Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the Relapsed/Refractory Acute Myeloid Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Relapsed/Refractory Acute Myeloid Leukemia Pipeline 2024
DelveInsight's, "Relapsed/refractory acute myeloid leukemia (AML) Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the Relapsed/Refractory Acute Myeloid Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Relapsed/Refractory Acute Myeloid Leukemia Emerging Drugs, Clinical Trials and P …
DelveInsight's, "Relapsed/refractory acute myeloid leukemia (AML) Pipeline Insight, 2024" report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
To explore more information on…
Relapsed/Refractory Acute Myeloid Leukemia Pipeline Outlook Report 2024
DelveInsight's, "Relapsed/refractory acute myeloid leukemia (AML) Pipeline Insight, 2024" report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Relapsed/Refractory…
Relapsed Refractory Multiple Myeloma Market Report 2024-2034 | Industry Size, Gr …
Market Overview:
The relapsed refractory multiple myeloma market reached a value of US$ 21.0 Billion in 2023 and expected to reach US$ 34.4 Billion by 2034, exhibiting a growth rate (CAGR) of 4.61% during 2024-2034.
The report offers a comprehensive analysis of the relapsed refractory multiple myeloma market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs…